Advertisement
News
Subscribe to MDT Magazine News

Maximizing the Potential of Multi-Drug Portfolios Without Cannibalizing from a Legacy Brand

December 10, 2010 10:33 am | by Bio-Medicine.Org | Comments

CHAPEL HILL, N.C., Dec. 10, 2010 /- Managing multiple brands for the same indication is a complex balancing act for bio-pharmaceutical companies. While a new product can translate into expanded market share and improved reputation with physicians, it can also result in a new product...

TOPICS:

Hanger Orthopedic shareholder plans $40M sale

December 10, 2010 9:45 am | by The Associated Press | Comments

Hanger Orthopedic Group Inc. said Friday that investor Ares Corporate Opportunities Fund is selling 2 million shares of Hanger stock for $20 per share.Hanger won't get any of the proceeds from the sale, which is expected to close Wednesday. The company said the shares were issued to Ares in...

BioVex launches Phase 3 study on head and neck cancer treatment

December 10, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Woburn-based biotech company BioVex Inc. today said that it has launched a Phase 3 study of its OncoVEXGM-CSF as a treatment for patients with locally advanced squamous cell carcinoma of the head and neck.

Advertisement

Molecular Insight files for Ch. 11

December 10, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Molecular Insight Pharmaceuticals, Inc. has filed for chapter 11 bankruptcy protection, in a deal that will secure the company a $45 million cash infusion from a private investment company.

Tomophase lung imaging device gets FDA OK

December 10, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | Comments

The U.S. Food and Drug Administration has granted 510(k) marketing clearance for Tomophase Corp.'s non-invasive Optical Coherence Tomography Imaging System (OCTIS).

Circulating Tumor Cells Predicted Recurrence, Death in Patients with Early-stage Breast Cancer

December 10, 2010 9:32 am | by AACR | Comments

SAN ANTONIO - The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III...

TOPICS:

High CTC Levels Predicted Poor Outcome in Metastatic Breast Cancer

December 10, 2010 9:31 am | by AACR | Comments

SAN ANTONIO - A high level of circulating tumor cells (CTCs) - cells that have detached from a tumor and are circulating in the body through the blood - are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level...

TOPICS:

Arrowhead CEO provides perspective on $4.5 million alliance between subsidiary Unidym and Samsung Electronics

December 10, 2010 8:34 am | by I-Micronews | Comments

Arrowhead Research Corporation's President and Chief Executive Officer today issued the following open letter to the Company's shareholders:

Advertisement

Nanostart-held ItN Nanovation receives equity commitment to support continued growth

December 10, 2010 8:34 am | by I-Micronews | Comments

ItN Nanovation AG, a portfolio company of Nanostart AG, has announced the signing of a conditional equity investment agreement of up to EUR 15 million with YA Global Master SPV Ltd., which is managed by Yorkville Advisors, LLC, a large U.S.-based investment group.

International collaboration boosts nanotechnology research

December 10, 2010 8:34 am | by I-Micronews | Comments

Despite their initial focus on national economic competitiveness, the nanotechnology research initiatives now funded by more than 60 countries have become increasingly collaborative, with nearly a quarter of all papers co-authored by researchers across borders.

Denosumab Delayed Time to First Skeletal-related Side Effect

December 10, 2010 8:32 am | by AACR | Comments

SAN ANTONIO - For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

TOPICS:

Photonics21 event to focus on FP8 priorities

December 10, 2010 7:37 am | by I-Micronews | Comments

European Commissioner Neelie Kroes will make a keynote address at the annual meeting of the Photonics21 European Technology Platform.

Innovative Micro Technology adds to its arsenal of through-silicon via offering

December 10, 2010 7:36 am | by I-Micronews | Comments

Innovative Micro Technology, Inc. (IMT) announced today the addition of a new geometry point in its technology roadmap for Through Silicon Vias (TSVs).

TSMC announces 3DIC Chip Technologies using TSVs

December 10, 2010 7:36 am | by I-Micronews | Comments

Taiwan Semiconductor Manufacturing Co Ltd (TSMC) had a lecture on its efforts to mass-produce 3D chips made by three-dimensionally stacking semiconductor chips by using its TSV (through silicon via) technology.

SABCS 2010: Interview with Ivis Febus-Sampayo

December 10, 2010 7:35 am | by AACR | Comments

Ms. Febus-Sampayo discusses the cultural challenges faced by Latina women when they receive a cancer diagnosis, shares advice about how clinicians can best serve the Latina women who have cancer, and the long-term goals of her organization.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading